e.nilsen

TL2 Moderator · Kumasi

Contributes reviews on supplier material. Based in Kumasi.

Joined 25 November 2024 · last posted 5d

77Posts here

1Topics

0Solutions

214Likes received

307Likes given

21Badges

129Days visited

1.3kPosts read

Recent activity

Full stream

Journal club: SUSTAIN 6 and its retinopathy signal Replied, post #105 · Evidence › Journal club · 23 Jul 2026 · 7 likes STEP 1 (N Engl J Med 2021): The pivotal obesity trial for semaglutide and the reference point for most subsequent comparison. Mean weight reduction was substantially…
[2026 update] Antibiotics and a course of something with delayed emptying Replied, post #75 · Practice › Interactions · 22 Jul 2026 · 3 likes Alcohol: no absolute contraindication but it raises gastrointestinal irritation risk and this drug class already does that. The conservative position during titration…
Compounds this community declines to help with, and why — does this still hold? Replied, post #7 · Compounds › Other compounds · 21 Jul 2026 · 2 likes Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the…
Here for the analytics and not much else Replied, post #50 · Lounge › Introductions · 18 Jul 2026 · 5 likes Ongoing: you can post multiple introductions over time. If you return after a long break, reintroducing yourself is fine.
Selection into a registry and what it does to the estimate — a second dataset Replied, post #17 · Evidence › Study critique · 14 Jul 2026 · 14 likes Confounding: in observational data, is there a third variable that explains the apparent association? In randomised data, randomisation should balance unknown…
Carryover and the ghost peak from last week's standard — what changed since Replied, post #111 · Analytics › HPLC & UHPLC · 5 Jul 2026 · 1 like Gradient slope is the single biggest driver of apparent purity differences. A shallower gradient over a longer run resolves more impurities and gives a higher purity…
Coming back to: Where the four-week escalation interval comes from, and what it is not Replied, post #11 · Practice › Dosing & titration · 4 Jul 2026 · 0 likes I read post #9 twice before replying, because I had assumed the opposite. The four-week escalation interval is a convention from the pivotal trials, not a…
Why this subcategory is stricter about sourcing than most Replied, post #49 · Compounds › Secretagogues & GH axis · 28 Jun 2026 · 2 likes Development history is more informative than speculation: ipamorelin was investigated clinically for post-operative ileus and was not taken forward to registration.…
Pinch or no pinch, and how needle length changes the answer — what changed since Replied, post #48 · Practice › Administration · 27 Jun 2026 · 23 likes A genuinely late dose: the labelling generally says that if the next dose is more than a couple of days away, take it as soon as you notice. If the next dose is close,…
Journal club: what we got wrong in an earlier session Replied, post #18 · Evidence › Journal club · 21 Jun 2026 · 0 likes FLOW (N Engl J Med 2024): Semaglutide renal outcomes in type 2 diabetes and chronic kidney disease. Stopped early for efficacy. Component-by-component analysis is…
Comparing my trajectory with the trial curves, carefully — a second dataset Replied, post #61 · Outcomes › Progress reports · 17 Jun 2026 · 1 like I read post #59 twice before replying, because I had assumed the opposite. Non-scale victories: muscle gain or maintenance, clothing fit, energy level, and capability…
Journal club: what we got wrong in an earlier session Replied, post #6 · Evidence › Journal club · 15 Jun 2026 · 11 likes I read post #4 twice before replying, because I had assumed the opposite. Critical appraisal template: (1) What did the trial set out to estimate? (2) Could the design…